Tirzepatide vs Semaglutide: Comparing GLP-1 Medications

Two Medications, Different Mechanisms

Semaglutide and tirzepatide both belong to the incretin-based therapy class, but they have a fundamental difference in how they work. Semaglutide is a pure GLP-1 receptor agonist, meaning it targets a single hormone pathway. Tirzepatide is a dual-action medication that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.

This dual mechanism is what makes tirzepatide unique. GIP is another incretin hormone that, when combined with GLP-1 activation, appears to enhance the effects on appetite suppression, insulin sensitivity, and fat metabolism. Think of semaglutide as playing one instrument very well, while tirzepatide plays two instruments at the same time.

Both medications are administered as once-weekly subcutaneous injections and follow a gradual dose-escalation protocol to minimize side effects. The similarities in administration make them easy to compare from a patient experience standpoint.

Head-to-Head Clinical Trial Results

The SURMOUNT trial program for tirzepatide and the STEP trial program for semaglutide provide the best data for comparison. While these weren't direct head-to-head trials (those have been limited), the results from similarly designed studies allow meaningful comparison.

In the STEP 1 trial, semaglutide 2.4 mg produced an average weight loss of 14.9% over 68 weeks. In the SURMOUNT-1 trial, tirzepatide at its highest dose (15 mg) produced an average weight loss of 22.5% over 72 weeks. Even at the mid-range dose (10 mg), tirzepatide averaged about 19.5% weight loss.

A 2023 real-world analysis published in JAMA Internal Medicine compared patients prescribed either medication and found that tirzepatide users lost approximately 5-7 more pounds on average over six months. However, the study also noted that individual responses vary widely, and some semaglutide users achieved results comparable to the best tirzepatide outcomes.

Side Effect Profiles Compared

The side effect profiles of both medications are remarkably similar, which isn't surprising given their shared mechanism of action on GLP-1 receptors. Nausea, diarrhea, vomiting, and constipation are the most commonly reported adverse events for both drugs.

In the SURMOUNT trials, nausea affected about 24-33% of tirzepatide users (depending on dose), compared to roughly 44% of semaglutide 2.4 mg users in STEP trials. However, direct comparison is difficult because trial populations and reporting methods varied. Some physicians observe that tirzepatide may have a slightly gentler GI side effect profile, but this hasn't been confirmed in a properly designed head-to-head trial.

Serious adverse events occurred at similar rates for both medications and were generally uncommon. Both drugs carry similar warnings regarding thyroid tumors (based on animal data), pancreatitis risk, and gallbladder disease. Neither medication should be used during pregnancy.

Dosing Schedules and Titration

Both medications are injected once weekly, which is a significant convenience factor compared to daily medications. The titration schedules differ somewhat in their specifics but follow the same philosophy: start low and increase gradually.

Semaglutide typically starts at 0.25 mg weekly and increases monthly in steps (0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) until the target dose is reached. The full titration takes about four to five months. Tirzepatide starts at 2.5 mg and increases in 2.5 mg increments every four weeks, reaching the maximum dose of 15 mg over about five months.

Both titration schedules can be adjusted by your physician based on tolerability. If side effects are significant at a given dose, staying at that level for an additional two to four weeks before increasing is common practice. At INA, our physicians tailor the schedule to each patient's response.

Cost and Accessibility in 2026

The pricing landscape for GLP-1 medications has shifted significantly since these drugs first launched. Brand-name Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) remain expensive at retail, often exceeding $1,000 per month without insurance.

Compounded versions of semaglutide, available through telehealth platforms like INA, offer a much more affordable entry point. Compounded semaglutide at INA starts at $155/mo* for the microdose option and $197/mo* for the standard injection (*6-month plan, first month pricing). These compounded formulations contain the same active ingredient prepared by licensed compounding pharmacies.

Tirzepatide availability through compounding has been more limited, and pricing tends to run higher than semaglutide. For many patients, the affordability of compounded semaglutide, combined with its strong efficacy data, makes it the practical choice.

Which Medication Is Better for You?

There's no universal answer. Based on current evidence, tirzepatide may produce slightly greater average weight loss, but semaglutide has a longer track record, more cardiovascular outcome data, and significantly better availability and pricing through compounded options.

Your physician at INA will consider your weight loss goals, medical history, budget, and preferences when making a recommendation. For most patients starting GLP-1 therapy, compounded semaglutide offers an excellent balance of clinical efficacy, safety data, cost, and convenience.

Some patients who don't respond as well to semaglutide may eventually transition to tirzepatide if it becomes more accessible. Others find that semaglutide, possibly combined with lifestyle changes and other supportive therapies, provides exactly the results they're looking for.

The Bottom Line

Both semaglutide and tirzepatide represent a genuine breakthrough in obesity medicine. They're the most effective weight loss medications ever developed, and they've changed how physicians approach chronic weight management.

The choice between them should be made with your doctor, based on your individual clinical picture, not based on marketing or social media hype. At INA, our physicians are experienced with GLP-1 medications and will guide you toward the option that gives you the best chance of meaningful, sustainable results.